macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...

Brain Cancer

According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...

Coronavirus

Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...

Veregen

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...

Singapore GDP grew more than expected in Q4

* Q4 GDP +3.3 pct q/q vs median forecast of +2.1 pct * Q4 GDP +1.5 pct y/y vs median forecast of +1.2 pct * Full-year 2012 GDP +1.3 percent * Singapore reiterates 2013 growth forecast of 1...

ALK-Abelló: Release date of nine-month interim report (Q3) 2012 for ALK

Copenhagen, 2012-10-29 16:13 CET (GLOBE NEWSWIRE) -- On Monday 12 November 2012, ALK releases its interim report for the nine months ended 30 September 2012. ALK will hold a conference call for ana...

Pfizer announces third-quarter 2012 dividend

The board of directors of Pfizer Inc. today declared a 22-cent third-quarter 2012 dividend on the company's common stock, payable September 5, 2012, to shareholders of record at the close of business...

Genmab A/S: Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

November 7, 2012; Copenhagen, Denmark; Interim Report for the 9 Months Ended September 30, 2012 Company Announcement -- Entered global license and development agreement for daratumumab with Janssen...

2012 RPS award winners announced

Nine Royal Pharmaceutical Society awards for 2012 were presented at a ceremony held in Birmingham this evening (9 September 2012)

Patient Safety Technologies Reports Third Quarter 2012 Results

IRVINE, Calif., Nov. 5, 2012 /- Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced results for its third quarter of 2012 ended September 30 th , 2012. Expand...

INGENICO: H1 2012 Results

Outstanding results in the first half of 2012 Significant growth across all regions * Very strong increase in H1 2012 revenue to EUR542.3 million, up 23% on a...

Sanofi: As expected, Q2 2012 Business EPS(1) impacted by the loss of exclusivity of Plavix(R) and Avapro(R) in the U.S.

PARIS, July 26, 2012, 2012 /PRNewswire/ -- Sanofi Q2 2012 Change on a Change at H1 2012 Change on a Change at reported...

The partial dopamine agonist pardoprunox (SLV308) administered in combination with L-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.

Dopamine agonist treatment in early Parkinson's disease (PD) induces less dyskinesia than L-dopa. However, once dyskinesia has developed, dopamine agonists administered with L-dopa exacerbate involunt...

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.

Long-acting full dopamine D(2) agonists produce less dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates and in Parkinson's disease than effective antiparkinsonian doses...

Author Reply: Discrepancies between the summary of characteristics and the recommended use of metformin in the treatment of type 2 diabetes mellitus patients.

Nefrologia 2012;32(6):838-9. doi: 10.3265/Nefrologia.pre2012.Oct.11783. Reply to: Del Pozo et al. Comment on Nefrologia 2012;32(6):837. Nefrologia 2012; 32(4):419-26.

ISS/SIC Donations January 2012 Through June 2012.

Author Reply: About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes.

Nefrologia 2012;32(6):835-7. doi: 10.3265/Nefrologia.pre2012.Oct.11731. Reply to: Serra Tarragon. Comment on Nefrologia 2012;32(6):835. Nefrologia 2012; 32(4):419-26.